A Critical Nexus:The Clinician and the Researcher.
14 July 2020
As clinician researchers, with busy clinical loads, our greatest challenge is ﬁnding time to engage deeply in the science. But it is necessary to deliver on our research goals.
The nexus between the clinician and the researcher is critical and underpins successful cancer research.
Embedded in every academic clinical cancer service there needs to be a vibrant program of research, which includes basic and translational research. Similarly, embedded in every cancer-related research laboratory, strong links to clinicians at the front line are essential. By working together, clinicians and scientists can gain insights beyond those easily achieved individually.
The clinician and scientist approach the cancer challenge from differing perspectives. Clinicians have a global perspective of the disease enabling them to identify what needs to change for maximal impact. Scientists tend to have a meticulous understanding of speciﬁc steps within complex biological systems - breaking the big picture into smaller parts, thus identifying opportunities for manipulation. Neither can successfully achieve the goal without the other.
This symbiotic relationship is well illustrated by modern cancer immunotherapy. For decades, clinicians recognised that immune manifestations correlated with good outcomes, but it was not until James Allison and Tasuko Honjo identiﬁed critical checkpoints in immune regulation that the opportunity to harness the immune system against cancer was realised. Now, checkpoint inhibitor drug therapies have transformed the cancer ﬁeld, highlighting what can be achieved when clinicians and scientists build upon their respective insights.
Article by Professor Georgina Long AO and Profesor Richard Scolyer, Melanoma Institute Australia and University of Sydney.
Read the full article Voices:Translating Basic Cancer Discoveries to the Clinic in Cancer Cell 37 here
Lucinda Ryan and Carole Renouf talking about melanoma preventation and awareness on 720 ABC Perth.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.